[p-(trifluoroacetamido)phenyl]ethyl 2-O-benzyl-3-O-(2,3,4,6-tetra-O-benzyl-β-D-glucopyranosyl)-4-O-(2-O-benzoyl-3,4,6-tri-O-benzyl-β-D-glucopyranosyl)-6-O-(3,4,6-tri-O-benzyl-2-O-chloroacetyl-β-D-glucopyranosyl)-α-D-glucopyranoside | 1352615-13-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: [p-(trifluoroacetamido)phenyl]ethyl 2-O-benzyl-3-O-(2,3,4,6-tetra-O-benzyl-β-D-glucopyranosyl)-4-O-(2-O-benzoyl-3,4,6-tri-O-benzyl-β-D-glucopyranosyl)-6-O-(3,4,6-tri-O-benzyl-2-O-chloroacetyl-β-D-glucopyranosyl)-α-D-glucopyranoside
• CAS: 1352615-13-4
• 化学式: C₁₂₀H₁₂₁ClF₃NO₂₄
• 分子量: 2053.72
• InChiKey: PUXINZDIOZOMMP-PZMHEENVSA-N

反应信息

• 作为反应物：
  描述：

  [p-(trifluoroacetamido)phenyl]ethyl 2-O-benzyl-3-O-(2,3,4,6-tetra-O-benzyl-β-D-glucopyranosyl)-4-O-(2-O-benzoyl-3,4,6-tri-O-benzyl-β-D-glucopyranosyl)-6-O-(3,4,6-tri-O-benzyl-2-O-chloroacetyl-β-D-glucopyranosyl)-α-D-glucopyranoside 在 碳酸氢钠 、 硫脲 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 10.0h， 以72%的产率得到[p-(trifluoroacetamido)phenyl]ethyl 2-O-benzyl-3-O-(2,3,4,6-tetra-O-benzyl-β-D-glucopyranosyl)-4-O-(2-O-benzoyl-3,4,6-tri-O-benzyl-β-D-glucopyranosyl)-6-O-(3,4,6-tri-O-benzyl-β-D-glucopyranosyl)-α-D-glucopyranoside
  参考文献：
  名称：

  Synthesis of a novel pentasaccharide core component from the lipooligosaccharide of Moraxella catarrhalis

  摘要：

  The novel pentasaccharide [p-(trifluoroacetamido)phenyl]ethyl 3-O-beta-D-glucopyranosyl-4-O-beta-D-glucopyranosyl-6-O-[2-O-(alpha-D-glucopyranosyl)-beta-D-glucopyranosyl]-alpha-D-glucopyranoside (1), which includes a linker moiety to enable facile coupling to an antigenic protein, was synthesised as a component of a potential vaccine candidate against the Gram-negative bacterium Moraxella catarrhalis. This microorganism is one of three principal causative agents of otitis media in children. The pentasaccharide represents a common cross-serotype (A, B and C) structure from the lipooligosaccharides of Moraxella catarrhalis. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.carres.2011.10.002
• 作为产物：
  描述：

  、 [p-(trifluoroacetamido)phenyl]ethyl 2-O-benzyl-3-O-(2,3,4,6-tetra-O-benzyl-β-D-glucopyranosyl)-4-O-(2-O-benzoyl-3,4,6-tri-O-benzyl-β-D-glucopyranosyl)-α-D-glucopyranoside 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.33h， 以576 mg的产率得到[p-(trifluoroacetamido)phenyl]ethyl 2-O-benzyl-3-O-(2,3,4,6-tetra-O-benzyl-β-D-glucopyranosyl)-4-O-(2-O-benzoyl-3,4,6-tri-O-benzyl-β-D-glucopyranosyl)-6-O-(3,4,6-tri-O-benzyl-2-O-chloroacetyl-β-D-glucopyranosyl)-α-D-glucopyranoside
  参考文献：
  名称：

  Synthesis of a novel pentasaccharide core component from the lipooligosaccharide of Moraxella catarrhalis

  摘要：

  The novel pentasaccharide [p-(trifluoroacetamido)phenyl]ethyl 3-O-beta-D-glucopyranosyl-4-O-beta-D-glucopyranosyl-6-O-[2-O-(alpha-D-glucopyranosyl)-beta-D-glucopyranosyl]-alpha-D-glucopyranoside (1), which includes a linker moiety to enable facile coupling to an antigenic protein, was synthesised as a component of a potential vaccine candidate against the Gram-negative bacterium Moraxella catarrhalis. This microorganism is one of three principal causative agents of otitis media in children. The pentasaccharide represents a common cross-serotype (A, B and C) structure from the lipooligosaccharides of Moraxella catarrhalis. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.carres.2011.10.002